The incidence of pancreatic neuroendocrine tumors (pNETs) continues to increase, prompting renewed interest in the pathophysiology and treatment of this disease. This focused series comprehensively reviews the pathophysiology, tumorigenesis, available clinical trials, and approved therapies for patients with pNETs. A deeper understanding of these factors is necessary to enhance our efforts to improve patient improve patient outcomes through the application of more innovative treatment sequencing.
Pancreatic neuroendocrine neoplasms: current state and ongoing controversies on terminology, classification and prognostication
The series “Pancreatic Neuroendocrine Tumors” was commissioned by the Editorial office, Journal of Gastrointestinal Oncology without any sponsorship or funding. Callisia N. Clarke and Douglas B. Evans served as the unpaid Guest Editors for the series.